LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era

References

• Warren AJ, Colledge WH, Carlton MB, . The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell 1994;78:45–57.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Pannell R, Forster A, . The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice. Proc Natl Acad Sci USA 2000;97:320–324.
   PubMed Web of Science ®Google Scholar
• Osada H, Grutz G, Axelson H, . Association of erythroid transcription factors: complexes involving the LIM protein RBTN2 and the zinc-finger protein GATA1. Proc Natl Acad Sci USA 1995;92: 9585–9589.
   PubMed Web of Science ®Google Scholar
• Wadman IA, Osada H, Grutz GG, . The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J 1997;16:3145–3157.
   PubMed Web of Science ®Google Scholar
• Boehm T, Foroni L, Kaneko Y, . The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci USA 1991;88:4367–4371.
   PubMed Web of Science ®Google Scholar
• Royer-Pokora B, Loos U, Ludwig WD. TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene 1991;6:1887–1893.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Czerwinski DK, Alizadeh AA, . Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004;350:1828–1837.
   PubMed Web of Science ®Google Scholar
• Natkunam Y, Zhao S, Mason DY, . The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood 2007;109:1636–1642.
   PubMed Web of Science ®Google Scholar
• Natkunam Y, Farinha P, Hsi ED, . LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol 2008;26:447–454.
   PubMed Web of Science ®Google Scholar
• Morton LM, Purdue MP, Zheng T, . Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer Epidemiol Biomarkers Prev 2009;18:1259–1270.
   PubMed Web of Science ®Google Scholar
• Morton LM, Cerhan JR, Hartge P, . Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study. Int J Mol Epidemiol Genet 2011;2:245–252.
   PubMedGoogle Scholar
• Habermann TM, Wang SS, Maurer MJ, . Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood 2008;112:2694–2702.
   PubMed Web of Science ®Google Scholar
• Percy C, Van Holten V, Muir C. International classification of diseases for oncology, second edition. Geneva: World Health Organization; 1990.
   Google Scholar
• Jaffe ES, Harris NL, Stein H, . World Health Organization classification of tumours: pathology and genetics, tumours of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
   Google Scholar
• Packer BR, Yeager M, Burdett L, . SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res 2006;34:D617–D621.
   PubMed Web of Science ®Google Scholar
• Carlson CS, Eberle MA, Rieder MJ, . Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004;74: 106–120.
   PubMed Web of Science ®Google Scholar
• Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972;34:187–220.
   Google Scholar
• Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70: 41–55.
   Web of Science ®Google Scholar
• Storey JD. A direct approach to false discovery rates. J R Stat Soc B 2002;64:479–498.
   Google Scholar
• Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56:337–344.
   PubMed Web of Science ®Google Scholar
• Kolbe D, Taylor J, Elnitski L, . Regulatory potential scores from genome-wide three-way alignments of human, mouse, and rat. Genome Res 2004;14:700–707.
   PubMed Web of Science ®Google Scholar
• Taylor J, Tyekucheva S, King DC, . ESPERR: learning strong and weak signals in genomic sequence alignments to identify functional elements. Genome Res 2006;16:1596–1604.
   PubMed Web of Science ®Google Scholar
• Pruess MM, Drechsler M, Royer-Pokora B. Promoter 1 of LMO2, a master gene for hematopoiesis, is regulated by the erythroid specific transcription factor GATA1. Gene Funct Dis 2000;2:87–94.
   Google Scholar
• Copie-Bergman C, Gaulard P, Leroy K, . Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. J Clin Oncol 2009;27:5573–5579.
   PubMed Web of Science ®Google Scholar
• Rimsza LM, Leblanc ML, Unger JM, . Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008;112:3425–3433.
   PubMed Web of Science ®Google Scholar
• Malumbres R, Chen J, Tibshirani R, . Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood 2008;111:5509–5514.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Warren AJ, Dobson C, . The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proc Natl Acad Sci USA 1998;95:3890–3895.
   PubMed Web of Science ®Google Scholar
• Gratzinger D, Zhao S, West R, . The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities. Am J Clin Pathol 2009;131: 264–278.
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Von Kalle C, Schmidt M, . LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302:415–419.
   PubMed Web of Science ®Google Scholar
• Ferrando AA, Neuberg DS, Staunton J, . Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002;1:75–87.
   PubMed Web of Science ®Google Scholar
• Larson RC, Fisch P, Larson TA, . T cell tumours of disparate phenotype in mice transgenic for Rbtn-2. Oncogene 1994;9:3675–3681.
   PubMed Web of Science ®Google Scholar
• Larson RC, Osada H, Larson TA, . The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice. Oncogene 1995;11:853–862.
   PubMed Web of Science ®Google Scholar
• Landry JR, Bonadies N, Kinston S, . Expression of the leukemia oncogene Lmo2 is controlled by an array of tissue-specific elements dispersed over 100 kb and bound by Tal1/Lmo2, Ets, and Gata factors. Blood 2009;113:5783–5792.
   PubMed Web of Science ®Google Scholar
• Felli N, Pedini F, Romania P, . MicroRNA 223-dependent expression of LMO2 regulates normal erythropoiesis. Haematologica 2009;94:479–486.
   PubMed Web of Science ®Google Scholar